Incyte today announced the expansion of its Moments of Clarity program, which amplifies the voices of people living with chronic immune-mediated skin conditions. This year, the initiative introduces ...

Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...

Incyte announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 ...

Additionally, in the U.S., MONJUVI® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with ...

Incyte (Nasdaq:INCY) today reported financial results for the third quarter of 2025 and provided a business update.

Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura ® (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who ...

The Canterbury-Bankstown Bulldogs are proud to announce the introduction of a refreshed Club logo, to be officially adopted from November 1. The new emblem represents a proud evolution of the Bulldogs ...

Transaction value calculated using the SEC Form 4 weighted average purchase price ($85.85) as of the transaction date (October 3, 2025); Post-transaction value calculated using the SEC Form 4 weighted ...

In response to this development, Stifel raised its price target for Incyte to $115, maintaining a Buy rating, citing improved visibility into growth prospects. In contrast, Oppenheimer downgraded ...

Incyte recently announced that its Phase 1 proof-of-concept studies for INCA33890 and INCB161734 will be featured as oral presentations at the 2025 European Society for Medical Oncology Congress, ...